Clinical content on this page follows South Florida Trim Clinic's editorial process for factual accuracy and alignment with current Semaglutide & GLP-1 Weight Management standards. This content is for educational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment. Full provider credentials are disclosed to enrolled patients. Medical Editorial Policy
Semaglutide Weight Loss
Semaglutide Weight Loss in Florida
Semaglutide is one of the most clinically studied medications in the history of medical weight management. South Florida Trim Clinic offers licensed-provider-reviewed semaglutide consultations for qualifying patients across Florida and 47 of the 50 U.S. states, excluding Alaska, Hawaii, and Arkansas — starting at $149/month.
Medical eligibility required. A provider must determine whether treatment is right for you.
Quick answer
What is semaglutide weight loss?
Semaglutide is a GLP-1 medication that may support weight loss by helping reduce appetite and quiet food noise for eligible patients. At South Florida Trim Clinic, Florida patients can access licensed-provider-reviewed semaglutide support through affordable telehealth, with eligibility determined after medical review. Results vary, and this content is educational, not medical advice.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — a medication that mimics the action of glucagon-like peptide-1, a hormone your body naturally produces to regulate appetite, blood sugar, and digestion. It was originally developed for type 2 diabetes management and was later recognized for its significant effects on weight.
Semaglutide is the active ingredient in both Ozempic® (approved for type 2 diabetes) and Wegovy® (approved for chronic weight management). Under medical supervision and after a thorough provider evaluation, semaglutide may be considered as part of a medically guided weight-loss program for qualifying patients.
Please note: Not every patient qualifies for semaglutide. A provider must review your full health history, current medications, and eligibility criteria before any prescription is issued. Side effects and contraindications must be reviewed.
How Semaglutide Works for Weight Loss
Semaglutide acts on GLP-1 receptors in the brain, gut, and pancreas to produce several effects that collectively support weight reduction in eligible patients:
What to Expect: Realistic Outcomes
Results vary from patient to patient. Some patients treated with semaglutide in clinical settings have experienced significant weight reduction over 12–16 months. Others see more modest results. Individual outcomes depend on starting weight, adherence, lifestyle factors, and how your body responds to the medication.
Semaglutide is not a cure for obesity. Medication may be one part of a broader weight-management plan that includes nutrition, physical activity, behavioral support, and ongoing medical oversight. Your South Florida Trim Clinic provider will help you set honest, achievable expectations from your very first consultation.
Common side effects include nausea, vomiting, diarrhea, constipation, and fatigue — particularly during the early weeks of treatment. These typically diminish as the body adjusts. Patients should discuss all side effects, risks, benefits, and alternatives with a licensed clinician before starting.
Why Choose South Florida Trim Clinic for Semaglutide?
We started in Naples, Florida, and we now serve eligible patients in 47 of the 50 U.S. states, excluding Alaska, Hawaii, and Arkansas, through 100% telehealth. Our clinic exists to make quality GLP-1 education and provider review easier to access.
We are not a pill factory that ships medication without meaningful oversight. Every patient receives a real consultation with a licensed provider, ongoing dosage management, and continuous access to our care team. We don't upsell. We don't bundle unnecessary services. We focus on licensed-provider-reviewed weight management that puts you first.
Learn More About Semaglutide & GLP-1 Care
Explore your options and how our telehealth program works before booking a free consultation.
Frequently Asked Questions
What is semaglutide and how does it support weight loss?+
Semaglutide is a GLP-1 receptor agonist that mimics a natural hormone involved in appetite, blood sugar, and digestion. It is the active ingredient in Ozempic® (for type 2 diabetes) and Wegovy® (for chronic weight management). For eligible patients, semaglutide may reduce appetite, slow gastric emptying, and quiet the 'food noise' many people describe, making it easier to eat less. It is prescribed under medical supervision, and a licensed provider must determine whether it is appropriate for you. Results vary and not everyone qualifies.
Who is a candidate for semaglutide treatment?+
Eligibility is determined by a licensed provider after reviewing your health history, current medications, and goals. Semaglutide is typically considered for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes or high blood pressure. Not everyone qualifies, and your provider will review risks, benefits, and alternatives before any prescription is issued. Telehealth availability may vary by state and patient eligibility.
What are the side effects of semaglutide?+
Common side effects can include nausea, vomiting, diarrhea, constipation, and fatigue, particularly during the early weeks as your dose is increased. These often diminish as your body adjusts. Semaglutide is not right for everyone, and certain medical conditions may make it inappropriate. You should review all potential side effects, contraindications, risks, and alternatives with a licensed clinician before starting. Your provider monitors your progress and can adjust your plan. Results vary from patient to patient.
How long does it take to see results with semaglutide?+
Results vary depending on starting weight, dose, adherence, lifestyle, and individual response. Treatment begins at a low dose and is gradually increased by your provider over several weeks. Appetite and weight changes may develop gradually over time. Semaglutide is not a cure for obesity and may be one part of a broader plan that includes nutrition, activity, and ongoing support. There are no guaranteed outcomes.
How is semaglutide different from tirzepatide?+
Both are once-weekly medications used in weight management reviewed by a licensed medical provider, but they work somewhat differently. Semaglutide acts on a single GLP-1 pathway, while tirzepatide activates two pathways — GLP-1 and GIP. The right option depends on your health history, any conditions like type 2 diabetes, and your provider's clinical assessment. Your South Florida Trim Clinic provider will help you compare them. Results vary and eligibility is determined by a licensed provider.
How much does semaglutide cost at South Florida Trim Clinic?+
South Florida Trim Clinic offers licensed-provider-reviewed semaglutide programs starting at $149 per month, which includes telehealth visits with a licensed provider, dosage management, and ongoing support, with free shipping when medication is prescribed. Medication ships from regulated pharmacies when medically appropriate. Final costs depend on the plan your provider recommends.
Clinical References & Sources
The following authoritative sources were referenced in preparing this educational content. All references are publicly available and verifiable.
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384:989–1002. [STEP 1 Trial] doi:10.1056/NEJMoa2032183
- Kushner RF, et al. "Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5." Obesity. 2020;28(6):1050–1061. doi:10.1002/oby.22794
- U.S. Food & Drug Administration. "Highlights of Prescribing Information: Wegovy (semaglutide) injection." 2021. FDA prescribing information
- U.S. Food & Drug Administration. "FDA Approves New Drug Treatment for Chronic Weight Management." June 4, 2021. fda.gov
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Prescription Medications to Treat Overweight & Obesity." niddk.nih.gov
Last reviewed: June 2026 · Medical content is for educational purposes only and is not a substitute for professional medical advice.
MEDICAL SOURCES & FURTHER READING
Check the source and its limits. The notes below explain which medical information each reference supports; they are not patient-specific advice or evidence of this clinic's results.
- Wegovy (semaglutide) injection — prescribing information
Sections 1–6 and the Medication Guide cover eligibility, dose escalation, GLP-1 action, gastrointestinal effects, thyroid-tumor warnings, pancreatitis, gallbladder disease, volume depletion and pregnancy precautions.
Evidence limits: This dated label is for FDA-approved Wegovy injection. Follow the current label for your specific product and your prescriber's instructions; it does not establish the safety or effectiveness of a compounded preparation.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
Research published in the New England Journal of Medicine reported greater average weight reduction with semaglutide 2.4 mg plus lifestyle intervention than placebo plus lifestyle intervention over 68 weeks in adults without diabetes. Nausea and diarrhea were common adverse events.
Evidence limits: A randomized trial of a defined dose/product and selected population, funded by Novo Nordisk. Not a clinic outcome, first-month forecast, or guarantee; results do not transfer automatically to compounded products.
- Prescription Medications to Treat Overweight & Obesity
Explains provider assessment, BMI and health considerations, medication mechanisms, use alongside nutrition and activity, treatment duration and possible weight regain after stopping.
Evidence limits: General education, not a determination of any patient's eligibility or an endorsement of this clinic.
- Understanding the Risks of Compounded Drugs
Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. Compounding may address a patient-specific medical need but carries quality and dosing risks.
RESEARCH & REFERENCES
- Wegovy (semaglutide) injection — prescribing information
U.S. Food and Drug Administration. FDA product labeling. 2025.
Read Wegovy (semaglutide) injection — prescribing information - Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding and colleagues. New England Journal of Medicine. 2021.
Read Once-Weekly Semaglutide in Adults with Overweight or Obesity - Prescription Medications to Treat Overweight & Obesity
National Institute of Diabetes and Digestive and Kidney Diseases (NIH). NIDDK patient education. Web resource; accessed 2026.
Read Prescription Medications to Treat Overweight & Obesity - Understanding the Risks of Compounded Drugs
U.S. Food and Drug Administration. FDA patient safety information. Web resource; accessed 2026.
Read Understanding the Risks of Compounded Drugs
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded preparations are not established as equivalent to FDA-approved products. Patient-specific need and applicable compounding requirements must be evaluated by the prescriber and pharmacy.
These independent information sources do not endorse, sponsor or affiliate with South Florida Trim Clinic. Education is not a substitute for individualized medical advice. Prescription treatment requires evaluation by an appropriately licensed healthcare provider.